A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Clinical trial NCT04274738 · COMPLETED
Trial details
- NCT number
- NCT04274738
- Sponsor
- X4 Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-30
- Primary completion
- 2022-10-31
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.